ReviewWorld journal of gastrointestinal surgery2018
Approach to pseudomyxoma peritonei.
Review in World journal of gastrointestinal surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 85 citations in OpenAlex.
- Outcome Analysis of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion (HITHOC) for Pseudomyxoma Peritonei with Pleural Metastasis.Annals of surgical oncology · 2026Article
- Risk Factors for Pseudomyxoma Peritonei in Appendiceal Mucinous Neoplasms: A Single-Center Experience.Cureus · 2026Article
- The Power of MUC2 in Mucinous Adenocarcinomas.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Review
- Case report and literature review: the effect of surgical management in intrathoracic pseudomyxoma peritonei.Frontiers in surgery · 2026Article
- Mucinase fromFrontiers in microbiology · 2026Article
- Classic multivisceral transplant for advanced nonresectable pseudomyxoma peritonei: a case report.Journal of medical case reports · 2025Article
- Bilateral pulmonary parenchymal metastasis from a low-grade appendiceal mucinous neoplasm.Journal of surgical case reports · 2025Article
- Pseudomyxoma Peritonei:Sultan Qaboos University medical journal · 2025Article
- Low-grade mucinous neoplasm originating from intestinal duplication: a case report and review of the literature.World journal of surgical oncology · 2025Review
- Article
- Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction.Frontiers in oncology · 2025Article
- Case Report: Insights into multiple cases of Pseudomyxoma peritonei.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Article
- Article
- Surveillance of low-grade appendiceal mucinous neoplasms for progression to pseudomyxoma peritonei: Results from a structured surveillance programme.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024Article
- Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Article
- Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.World journal of surgical oncology · 2024Article
- Review
- A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Clinical journal of gastroenterology · 2024Article
- Long-term survival in patients with PMP: a single-institutional retrospective study from China.World journal of surgical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomyxoma peritonei (PMP) is a mucinous tumour of the appendix that spreads into the peritoneal cavity in the form of gelatinous deposits. The incidence of PMP is believed to be approximately 1-3 out of a million per year. Nonetheless, due to its indolent nature, it is usually discovered at an advanced stage and severely impacts quality of life. Curative treatment for PMP is complete cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). An extensive literature review was conducted searching EMBASE, MEDLINE, PubMed, and Google Scholar databases for PMP in aims to delineate a clinical approach to diagnosis and treatment. Literature was limited to the years 2007-2018. We found the 5-year overall survival with CRS and HIPEC estimated to be between 23%-82% and rates of major complications as high as 24%. Therefore, it is important to appropriately stage and select patients that should undergo CRS with HIPEC. Modalities like MDCT radiological scores have been shown to have sensitivity and specificity of 94% and 81%, respectively, in being able to predict resectability and survival. Despite treatment, the disease often recurs. Tumor markers have significant potential for establishing prognosis pre-operatively, and this paper will review the most recent evidence in support of them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.